Drugs / G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02104427 Background | Feb → Nov 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02104427 ↗ |
| Route | Subcutaneous | “G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8” NCT02104427 ↗ |